Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06130553 · ClinicalTrials.gov registry record · Phase 1
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
A Phase 1 study of Advanced Solid Tumors That Are MTAP Deficient, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 234
- Enrollment target
- 20
- Study locations
NCT06130553 is a Phase 1 study of Advanced Solid Tumors That Are MTAP Deficient that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 234 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT06130553, a Phase 1 study of Advanced Solid Tumors That Are MTAP Deficient, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 234 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.
Conditions Studied
Interventions
- DRUG AZD3470
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Beijing
- Research Site - Chengdu
- Research Site - Shanghai
- Research Site - Villejuif
- Research Site - Chūōku
- Research Site - Kashiwa
- Research Site - Amsterdam
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Madrid
California
- Research Site - San Francisco
- Research Site - West Hollywood
Connecticut
- Research Site - New Haven
Maryland
- Research Site - Baltimore
Oregon
- Research Site - Portland
Pennsylvania
- Research Site - Pittsburgh
Rhode Island
- Research Site - Providence
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2026-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06130553
The ClinicalTrials.gov registry entry for NCT06130553 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors That Are MTAP Deficient appearing as the primary indexed condition, and to 1 intervention - of which AZD3470 is the first listed.
NCT06130553 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06130553 about?
NCT06130553 is a clinical study titled "A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors". This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and pre...
What is the current status of trial NCT06130553?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2024-01-18. Estimated completion is 2026-02-26.
What conditions does trial NCT06130553 study?
This clinical trial studies the following conditions: Advanced Solid Tumors That Are MTAP Deficient.
What interventions are being tested in trial NCT06130553?
The interventions under investigation include: AZD3470 (DRUG).
Who is sponsoring clinical trial NCT06130553?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06130553 being conducted?
This trial has 20 study locations across California, Connecticut, Maryland, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.